It looks like you're new here. If you want to get involved, click one of these buttons!
If you read all my comments at length in the earlier thread that explains the issue in a lot of detail, you might find it less opaque. :-)
Cman usually offers insightful comments, but he's become a bit opaque for me this time.
Is the S & P the fund's benchmark? I'm guessing no.According to M*, RNCOX does not exceed the S&P by it's ER over the last 1 and 3 years.
Is it time to abandon this previously recommended "Core Fund?"
I've sold off 2/3 over the past 2 years. Is it time to abandon the remaining third?
@fundalarm
Hi,
Our house is again playing more in bondland; ....so, far; so good. Equity down to 15% as of the end of February. Two largest equity are currently PRHSX and VSCPX and the equity mixes among FAGIX and LSBDX, in general; with a touch of equity inside of FRIFX.
Hoping all is well with you and yours.
Take care,
Catch
@mona, @johnchisum it is better to follow trends such as
How technology hurts health providers
for investing purposes than be distracted by political ideology colored data (on either side of spectrum).
The changes mentioned in that article above are real and powerful and much more relevant in the market place. I already see significant advertising locally here for clinics inside CVS.
The release of payment data from Medicare payments is significantly going to change how providers and drugs see the money because of public backlash on the use of Medicare funds - a bad sign for biotechs with high priced drugs that were flying under the radar until now and making large profits.
© 2015 Mutual Fund Observer. All rights reserved.
© 2015 Mutual Fund Observer. All rights reserved. Powered by Vanilla